Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29872769 | 0.81 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDKMT2AGLA | |
| SCHEMBL243950 | 0.81 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDKMT2AGLA | |
| SCHEMBL10112536 | 0.80 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDKMT2AMAPK14 | |
| SCHEMBL28032688 | 0.80 | KDM4E (0.61) | ALDH1A1KDM4EHPGDKMT2AGLA | |
| SCHEMBL6843188 | 0.80 | ALDH1A1 (0.66) | ALDH1A1KDM4EHPGDKMT2AGLA | |
| SCHEMBL13363100 | 0.80 | KDM4E (0.61) | ALDH1A1KDM4EHPGDKMT2AGLA | |
| SCHEMBL27608904 | 0.79 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDKMT2AGLA | |
| SCHEMBL5361244 | 0.79 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDKMT2AGLA | |
| SCHEMBL17505983 | 0.79 | KDM4E (0.59) | ALDH1A1KDM4EHPGDKMT2AMAPK14 | |
| SCHEMBL30211300 | 0.79 | MAPK14 (0.53) | MAPK14MAPK10BCHEPDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021444-B2 | Antiviral compounds | Janssen Biopharma, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2018-03-08 | — | — | US | disclosed |
| US-20150065504-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150065504-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2015-03-05 | — | — | US | disclosed |
| WO-2015026792-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2015-02-26 | — | — | WO | disclosed |
| EP-1551832-A1 | 8-AZABICYCLO[3.2.1]OCTANE ETHER DERIVATIVES AND THEIR USE AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2005-07-13 | — | — | EP | disclosed |
| US-6727249-B2 | FOR THERAPY AND PROPHYLAXIS OF PAIN OR INFLAMMATION, MIGRAINE, EMESIS, POSTHERPETIC NEURALGIA, DEPRESSION OR ANXIETY | MERCK SHARP & DOHME LTD. (GB) | 2004-04-27 | — | — | US | disclosed |
| WO-2004031185-A1 | 8-AZABICYCLO[3.2.1]OCTANE ETHER DERIVATIVES AND THEIR USE AS NEUROKININ RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
| US-20020193402-A1 | Azabicyclic ether derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | ALDH1A1 4011/4885KDM4E 3737/4885HPGD 3636/4885 |
| US-11021444-B2 | Antiviral compounds | MAVS, SARS1, ZC3HAV1 | ALDH1A1 4011/4885KDM4E 3737/4885HPGD 3636/4885 |
| US-20020193402-A1 | Azabicyclic ether derivatives and their use as therapeutic agents | CXCR1, OPRM1, GRM1 | ALDH1A1 2179/4885KDM4E 772/4885HPGD 2559/4885 |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | ALDH1A1 4011/4885KDM4E 3737/4885HPGD 3636/4885 |
| US-20150065504-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | ALDH1A1 4011/4885KDM4E 3737/4885HPGD 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.